Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02575703 · ClinicalTrials.gov registry record · Phase 1
A Study of [¹⁴C]-LY3023414 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02575703 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 8 participants.
The verdict
NCT02575703, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This type of study is called a radiolabeled study. For this study, LY3023414 has been specially prepared to contain the radioactive carbon atom \[¹⁴C\]. \[¹⁴C\] is a naturally occurring radioactive form of the element carbon. Adding a low dose of radiation to the study drug does not change how the drug works but helps to identify when the drug appears in the blood, urine, breath, and stool after it is given. The study will last about 15 days for each participant, not including screening. Screening is required within 28 days prior to enrollment. This study is for research purposes only and is not intended to treat any medical condition.
Interventions
- DRUG [¹⁴C]-LY3023414
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-10 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02575703
The ClinicalTrials.gov registry entry for NCT02575703 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [¹⁴C]-LY3023414 is the first listed.
NCT02575703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02575703 about?
NCT02575703 is a clinical study titled "A Study of [¹⁴C]-LY3023414 in Healthy Participants". This type of study is called a radiolabeled study. For this study, LY3023414 has been specially prepared to contain the radioactive carbon atom \[¹⁴C\]. \[¹⁴C\] is a naturally occurring radioactive form of the element carbon. Adding a low dose of radiation to the study drug does not change how the d...
What is the current status of trial NCT02575703?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-10. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02575703?
The interventions under investigation include: [¹⁴C]-LY3023414 (DRUG).
Who is sponsoring clinical trial NCT02575703?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.